Go to IVREA Home Page IVREA Header

 

Daniel S. Lynch
President and CEO

Dan Lynch is the President, CEO and a Director of Ivrea Pharmaceuticals. He also serves on the Board of Directors and the Audit Committee of U.S. Oncology, Inc.

Previously, Dan served as CFO and then CEO and a Director of ImClone Systems Inc. Prior to ImClone, he held the position of Chief Financial Officer of Derby Cycle Corporation. Dan also served for 15 years in various financial capacities at Bristol-Myers Squibb Company, including Vice President positions for the U.S. Pharmaceuticals business, Worldwide Manufacturing operations, International Pharmaceuticals business, and the Worldwide Consumer Medicines business.

Dan received his Bachelor of Arts in Mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at The University of Virginia.

David Neafus
CFO

David Neafus has served as our CFO since March 2008. Over the previous twelve years, Dave operated his own consulting firm providing executive services, specializing in interim executive management, IPO’s, turnarounds, strategic analysis, and mergers and acquisitions. Previous clients include GlycoFi, where as CFO David helped the Company complete its $400 Million acquisition by Merck, Alnylam Pharmaceuticals, Inc. where as Vice President of Finance David led the company to a successful IPO, Infinity Pharmaceuticals where David served as Vice President Finance and Administration and Millennium Pharmaceuticals where he served as Corporate Controller.

Prior to running his own consulting firm, David was an auditor at KPMG. Mr. Neafus received his bachelor’s degree in accounting from the University of Minnesota, and his MBA from Bentley College.

He is also a certified public accountant.

 

Experienced pharmaceutical professionals with dermatology expertise

“I am both honored and excited to lead a company with such promising programs in the field of dermatology. We are very fortunate to have an incredibly experienced, talented, and dedicated team, which I am confident will successfully develop our current products, as well as others in the future.”

Daniel Lynch, CEO and President, Ivrea

Copyright © 2007 Ivrea Pharmaceuticals. All rights reserved.